Derek Nigel John Hart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Derek Nigel John Hart has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Slavica Vuckovic
Mater Medical Research Institute, South Brisbane, Australia
5 shared publications- José Alejandro Lopez
QIMR Berghofer Medical Research Institute, Brisbane, Australia
3 shared publications - Kristen Jane Radford
Mater Research Institute, The University of Queensland, Brisbane, Australia
3 shared publications - Andrew J. Kassianos
Kidney Health Service Royal Brisbane and Women's Hospital Herston Queensland Australia
2 shared publications Christopher S. K. Ho
Dendritic Cell Laboratory, Mater Medical Research Institute, Brisbane, Australia
2 shared publicationsDavid J. Munster
Mater Medical Research Institute, South Brisbane, Australia
2 shared publications
Latest Publications
- 1 February 2009
- Published by Springer Nature in Science-Business eXchange
- Vol. 2 (6) , 245
CD83
- Open Access
- 26 January 2009
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 206 (2) , 387-398
Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease
Allogeneic (allo) hematopoietic stem cell transplantation is an effective therapy for hematological malignancies but it is limited by acute graft-versus-host disease (GVHD). Dendritic cells (DC) play a major role in the allo T cell stimulation causing GVHD. Current immunosuppressive measures to control GVHD target T cells but compromise posttransplant immunity in the patient, particularly to cytomegalovirus (CMV) and residual malignant cells. We showed that treatment of allo mixed lymphocyte cultures with activated human DC-depleting CD83 antibody suppressed alloproliferation but preserved T cell numbers, including those specific for CMV. We also tested CD83 antibody in the human T cell–dependent peripheral blood mononuclear cell transplanted SCID (hu-SCID) mouse model of GVHD. We showed that this model requires human DC and that CD83 antibody treatment prevented GVHD but, unlike conventional immunosuppressants, did not prevent engraftment of human T cells, including cytotoxic T lymphocytes (CTL) responsive to viruses and malignant cells. Immunization of CD83 antibody-treated hu-SCID mice with irradiated human leukemic cell lines induced allo antileukemic CTL effectors in vivo that lysed 51Cr-labeled leukemic target cells in vitro without further stimulation. Antibodies that target activated DC are a promising new therapeutic approach to the control of GVHD.
- 26 January 2009
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 206 (2) , 387-398
Open AccessAntibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease
Allogeneic (allo) hematopoietic stem cell transplantation is an effective therapy for hematological malignancies but it is limited by acute graft-versus-host disease (GVHD). Dendritic cells (DC) play a major role in the allo T cell stimulation causing GVHD. Current immunosuppressive measures to control GVHD target T cells but compromise posttransplant immunity in the patient, particularly to cytomegalovirus (CMV) and residual malignant cells. We showed that treatment of allo mixed lymphocyte cultures with activated human DC-depleting CD83 antibody suppressed alloproliferation but preserved T cell numbers, including those specific for CMV. We also tested CD83 antibody in the human T cell–dependent peripheral blood mononuclear cell transplanted SCID (hu-SCID) mouse model of GVHD. We showed that this model requires human DC and that CD83 antibody treatment prevented GVHD but, unlike conventional immunosuppressants, did not prevent engraftment of human T cells, including cytotoxic T lymphocytes (CTL) responsive to viruses and malignant cells. Immunization of CD83 antibody-treated hu-SCID mice with irradiated human leukemic cell lines induced allo antileukemic CTL effectors in vivo that lysed 51Cr-labeled leukemic target cells in vitro without further stimulation. Antibodies that target activated DC are a promising new therapeutic approach to the control of GVHD.
- 14 October 2008
- Published by Wiley in British Journal of Haematology
- Vol. 143 (3) , 374-377
Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma
Summary: Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio‐process to purify CMRF‐56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF‐56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% (n = 6, purity 28%). Preparations from MM patients (n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.
- 14 October 2008
- Published by Wiley in British Journal of Haematology
- Vol. 143 (3) , 374-377
Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma
Summary: Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio‐process to purify CMRF‐56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF‐56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% (n = 6, purity 28%). Preparations from MM patients (n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.
- 15 April 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (7) , 839-846
Activated Circulating Dendritic Cells After Hematopoietic Stem Cell Transplantation Predict Acute Graft-Versus-Host Disease
Background. Dendritic cells (DC) are central to the development of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (alloHSCT). We hypothesized that DC activation status determines the severity of GVHD and that activated DC may be detected in the circulation prior to clinical presentation of GVHD. Methods. Following transplant, blood samples were obtained twice weekly from alloHSCT patients. Myeloid (CD11c+) and plasmacytoid (CD123hi) DC were enumerated by flow cytometry, and activated myeloid DC were identified using the CMRF-44 monoclonal antibody. Results. Of 40 alloHSCT patients, 26 developed acute GVHD. Severity of GVHD was associated with low total blood DC counts (P=0.007) and with low myeloid and plasmacytoid DC numbers (P=0.015 and 0.003). The CMRF-44 antigen was expressed on blood CD11c+ DC in all cases prior to GVHD onset, whereas of the 14 patients without GVHD, seven had no CMRF-44+ CD11c+ DC. Patients with CMRF-44+ CD11c+ DC in more than 20% of samples were more likely to subsequently develop acute GVHD (P=0.001, odds ratio=37.1), while patients who developed grade 2–4 GVHD had prior higher percentages of CMRF-44+ CD11c+ DC compared to grade 0–1 GVHD patients (P=0.001). CMRF-44 expression on >7.9% CD11c+ DC predicted for subsequent development of GVHD with a sensitivity of 87.5% and specificity of 79.2%. Conclusions. Activation status, as assessed by CMRF-44 antigen expression, of blood CD11c+ DC is highly associated with acute GVHD and these cells may be targets for therapeutic intervention.
- 15 April 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (7) , 839-846
Activated Circulating Dendritic Cells After Hematopoietic Stem Cell Transplantation Predict Acute Graft-Versus-Host Disease
Background. Dendritic cells (DC) are central to the development of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (alloHSCT). We hypothesized that DC activation status determines the severity of GVHD and that activated DC may be detected in the circulation prior to clinical presentation of GVHD. Methods. Following transplant, blood samples were obtained twice weekly from alloHSCT patients. Myeloid (CD11c+) and plasmacytoid (CD123hi) DC were enumerated by flow cytometry, and activated myeloid DC were identified using the CMRF-44 monoclonal antibody. Results. Of 40 alloHSCT patients, 26 developed acute GVHD. Severity of GVHD was associated with low total blood DC counts (P=0.007) and with low myeloid and plasmacytoid DC numbers (P=0.015 and 0.003). The CMRF-44 antigen was expressed on blood CD11c+ DC in all cases prior to GVHD onset, whereas of the 14 patients without GVHD, seven had no CMRF-44+ CD11c+ DC. Patients with CMRF-44+ CD11c+ DC in more than 20% of samples were more likely to subsequently develop acute GVHD (P=0.001, odds ratio=37.1), while patients who developed grade 2–4 GVHD had prior higher percentages of CMRF-44+ CD11c+ DC compared to grade 0–1 GVHD patients (P=0.001). CMRF-44 expression on >7.9% CD11c+ DC predicted for subsequent development of GVHD with a sensitivity of 87.5% and specificity of 79.2%. Conclusions. Activation status, as assessed by CMRF-44 antigen expression, of blood CD11c+ DC is highly associated with acute GVHD and these cells may be targets for therapeutic intervention.
- 1 November 2006
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 29 (6) , 596-605
CD11c+ Blood Dendritic Cells Induce Antigen-specific Cytotoxic T Lymphocytes With Similar Efficiency Compared to Monocyte-derived Dendritic Cells Despite Higher Levels of MHC Class I Expression
Dendritic cell (DC) immunotherapy for cancer has shown promising results in phase I and II clinical trials. Most studies have used monocyte-derived DCs (MoDCs) but their poor migratory capacity in vivo has emerged as a key issue. The natural circulating peripheral blood CD11c+ DC precursors (BDCs) may be an attractive alternative to MoDCs, as they can be isolated rapidly in sufficient quantities, and have superior migratory and T helper-1-inducing capacity in vitro. We performed the first comparative analysis of the ability of autologous BDCs and MoDCs in healthy donors to induce tumor-specific cytotoxic T lymphocytes (CTLs). BDCs expressed significantly higher levels of major histocompatibility complex class I and CD83 in the absence of exogenous stimuli compared with MoDCs. After activation with polyinosinic-polycytidylic acid, BDCs expressed higher levels of major histocompatibility complex class I, CD40, CD80, and CD83, and secreted higher levels of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-8 compared with MoDCs. Despite these differences, both preparations secreted similar levels of IL-12 in response to polyinosinic-polycytidylic acid and, importantly, induced CTL responses of similar magnitude and affinity against influenza matrix protein and MART-1. The ability of BDCs to induce efficient CTL responses, combined with their migratory capacity, makes them an appealing alternative to be investigated in clinical immunotherapy research protocols.
- 1 November 2006
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 29 (6) , 596-605
CD11c+ Blood Dendritic Cells Induce Antigen-specific Cytotoxic T Lymphocytes With Similar Efficiency Compared to Monocyte-derived Dendritic Cells Despite Higher Levels of MHC Class I Expression
Dendritic cell (DC) immunotherapy for cancer has shown promising results in phase I and II clinical trials. Most studies have used monocyte-derived DCs (MoDCs) but their poor migratory capacity in vivo has emerged as a key issue. The natural circulating peripheral blood CD11c+ DC precursors (BDCs) may be an attractive alternative to MoDCs, as they can be isolated rapidly in sufficient quantities, and have superior migratory and T helper-1-inducing capacity in vitro. We performed the first comparative analysis of the ability of autologous BDCs and MoDCs in healthy donors to induce tumor-specific cytotoxic T lymphocytes (CTLs). BDCs expressed significantly higher levels of major histocompatibility complex class I and CD83 in the absence of exogenous stimuli compared with MoDCs. After activation with polyinosinic-polycytidylic acid, BDCs expressed higher levels of major histocompatibility complex class I, CD40, CD80, and CD83, and secreted higher levels of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-8 compared with MoDCs. Despite these differences, both preparations secreted similar levels of IL-12 in response to polyinosinic-polycytidylic acid and, importantly, induced CTL responses of similar magnitude and affinity against influenza matrix protein and MART-1. The ability of BDCs to induce efficient CTL responses, combined with their migratory capacity, makes them an appealing alternative to be investigated in clinical immunotherapy research protocols.
- 1 April 2006
- Vol. 47 (4) , 572-3
Dendritic cells in leukemia and lymphoma.
- 19 September 2005
- Published by Wiley in The Prostate
- Vol. 66 (2) , 180-192
Numerical and functional assessment of blood dendritic cells in prostate cancer patients
BACKGROUND Prostate cancer is one of the leading causes of cancer deaths in males and there are currently no effective treatments available for metastatic disease. Although recent clinical trials using dendritic cell (DC) based immunotherapy treatments have demonstrated safety, immunological responses, and some clinical efficacy, better vaccine delivery strategies need to be developed. We have undertaken the first detailed analysis of blood DC (BDC) subsets and their function in prostate cancer patients, with a view to utilizing immunoselected BDC for immunotherapy. METHODS We enumerated the CD11c+CD1c+, CD11c+CD16+, and CD11c−CD123+ BDC subsets in whole blood of prostate cancer patients using a single platform TruCOUNT™ assay. These subsets were identified and purified using flow cytometry and immunomagnetic selection, and their functional capacity analyzed by costimulatory molecule expression, cytokine secretion, and antigen presenting ability. RESULTS There were no significant differences in the number or composition of these subsets compared to healthy donors and these cells could be purified with equal efficiency from both groups. The prostate cancer patients BDC had similar levels of key costimulatory molecules and cytokine expression profiles, compared to healthy donors, and these were upregulated to the same extent, in response to exogenous stimuli. BDC from both groups were capable of eliciting allogeneic proliferative responses and inducing autologous CD4+ responses to naïve and recall antigens, and antigen‐specific CD8+ responses to influenza matrix protein and prostate specific antigen. CONCLUSIONS These results indicate that an immunoselected CD1c+ BDC preparation could provide a suitable vaccine delivery vehicle for future prostate cancer immunotherapy trials.
- 19 September 2005
- Published by Wiley in The Prostate
- Vol. 66 (2) , 180-192
Numerical and functional assessment of blood dendritic cells in prostate cancer patients
BACKGROUND Prostate cancer is one of the leading causes of cancer deaths in males and there are currently no effective treatments available for metastatic disease. Although recent clinical trials using dendritic cell (DC) based immunotherapy treatments have demonstrated safety, immunological responses, and some clinical efficacy, better vaccine delivery strategies need to be developed. We have undertaken the first detailed analysis of blood DC (BDC) subsets and their function in prostate cancer patients, with a view to utilizing immunoselected BDC for immunotherapy. METHODS We enumerated the CD11c+CD1c+, CD11c+CD16+, and CD11c−CD123+ BDC subsets in whole blood of prostate cancer patients using a single platform TruCOUNT™ assay. These subsets were identified and purified using flow cytometry and immunomagnetic selection, and their functional capacity analyzed by costimulatory molecule expression, cytokine secretion, and antigen presenting ability. RESULTS There were no significant differences in the number or composition of these subsets compared to healthy donors and these cells could be purified with equal efficiency from both groups. The prostate cancer patients BDC had similar levels of key costimulatory molecules and cytokine expression profiles, compared to healthy donors, and these were upregulated to the same extent, in response to exogenous stimuli. BDC from both groups were capable of eliciting allogeneic proliferative responses and inducing autologous CD4+ responses to naïve and recall antigens, and antigen‐specific CD8+ responses to influenza matrix protein and prostate specific antigen. CONCLUSIONS These results indicate that an immunoselected CD1c+ BDC preparation could provide a suitable vaccine delivery vehicle for future prostate cancer immunotherapy trials.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 2599
A phase I clinical trial of a BDCA-1+ blood dendritic cell preparation loaded with control and tumour-associated antigens, for immune therapy of metastatic refractory prostate cancer
2599 Background: In vitro loaded dendritic cells (DC) are a promising new treatment for patients with prostate cancer. Blood DC (BDC) preparations may be an attractive alternative to the more commonly used monocyte-derived DC (MoDC) in terms of performance, logistics, cost and regulatory issues. In preclinical studies, we have shown that CD1c+ BDC can be isolated from prostate cancer patients with equivalent numerical and functional integrity compared to healthy donors, justifying their use as a platform for immunotherapy. Methods: We have validated a procedure for the isolation of CD1c+ BDC by positive immunoselection using the CliniMACS system that is suitable for clinical use. BDC isolated from HLA-A*0201+ patients are pulsed with PSA-3, PSMA-2, PAP-5, and influenza matrix protein (FMP) peptides. Patients receive 3 i.d. or i.v. injections at monthly intervals. Results: We are currently investigating cell yields, purity and functionality of this cell preparation. Approximately 0.12% of mononuclear cells obtained by leukapheresis are recovered with greater than 80% purity. Conclusions: Our data shows that sufficient BDCA-1+ BDC can be isolated using this system for a vaccine regimen. A Phase I trial to establish safety and efficacy in prostate cancer patients is currently underway. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 2599
A phase I clinical trial of a BDCA-1+ blood dendritic cell preparation loaded with control and tumour-associated antigens, for immune therapy of metastatic refractory prostate cancer
2599 Background: In vitro loaded dendritic cells (DC) are a promising new treatment for patients with prostate cancer. Blood DC (BDC) preparations may be an attractive alternative to the more commonly used monocyte-derived DC (MoDC) in terms of performance, logistics, cost and regulatory issues. In preclinical studies, we have shown that CD1c+ BDC can be isolated from prostate cancer patients with equivalent numerical and functional integrity compared to healthy donors, justifying their use as a platform for immunotherapy. Methods: We have validated a procedure for the isolation of CD1c+ BDC by positive immunoselection using the CliniMACS system that is suitable for clinical use. BDC isolated from HLA-A*0201+ patients are pulsed with PSA-3, PSMA-2, PAP-5, and influenza matrix protein (FMP) peptides. Patients receive 3 i.d. or i.v. injections at monthly intervals. Results: We are currently investigating cell yields, purity and functionality of this cell preparation. Approximately 0.12% of mononuclear cells obtained by leukapheresis are recovered with greater than 80% purity. Conclusions: Our data shows that sufficient BDCA-1+ BDC can be isolated using this system for a vaccine regimen. A Phase I trial to establish safety and efficacy in prostate cancer patients is currently underway. No significant financial relationships to disclose.
- 1 January 2005
- Published by Elsevier in The Lancet
- Vol. 365 (9454) , 102-104
Dendritic cell biology evolves into clinical application
- 1 January 2005
- Published by Elsevier in The Lancet
- Vol. 365 (9454) , 102-104
Dendritic cell biology evolves into clinical application
- Open Access
- 1 January 2004
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 16 (1) , 33-42
Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity
CD83 is a marker of dendritic cell (DC) differentiation/activation and its expression in the mouse thymus contributes to CD4+ T lymphocyte development. Its extrathymic role remains unclear despite the functional effects observed with CD83 fusion proteins or CD83 antibody and recent reports of potential ligands. We investigated the previously observed and presumed functional blockade of the allogeneic mixed leukocyte reaction (MLR) with rabbit polyclonal anti‐CD83 (RA83). RA83 inhibition of T lymphocyte proliferation stimulated with allogeneic immature monocyte‐derived DC (iMoDC) was confirmed. However, we found it was due to antibody‐dependent cellular cytotoxicity (ADCC) mediated by NK cells in the responder T cell preparation. The likely targets of the ADCC were MoDC that had up‐regulated CD83 during the MLR. Using a 51Cr‐release assay, we confirmed that CD83+ MoDC, but not CD83– MoDC, are lysed by NK cells in the presence of RA83. However, prior fixation of the stimulator MoDC in the allogeneic MLR did not abrogate RA83 inhibition, indicating that cells from the responder T lymphocyte preparation, involved in the MLR proliferative response, also expressed CD83. We found, after 3–4 days of culture with allogeneic MoDC, a subset of CD3+ cells had up‐regulated CD83 and CD25. These were blasting T cells and, when isolated from the MLR, were found to be lysed by autologous NK cells in the presence of RA83. Thus, CD83 is expressed by responding T cells as well as by stimulating cells in the MLR and both are susceptible to anti‐CD83‐mediated ADCC.
- 1 January 2004
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 16 (1) , 33-42
Open AccessHuman T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity
CD83 is a marker of dendritic cell (DC) differentiation/activation and its expression in the mouse thymus contributes to CD4+ T lymphocyte development. Its extrathymic role remains unclear despite the functional effects observed with CD83 fusion proteins or CD83 antibody and recent reports of potential ligands. We investigated the previously observed and presumed functional blockade of the allogeneic mixed leukocyte reaction (MLR) with rabbit polyclonal anti‐CD83 (RA83). RA83 inhibition of T lymphocyte proliferation stimulated with allogeneic immature monocyte‐derived DC (iMoDC) was confirmed. However, we found it was due to antibody‐dependent cellular cytotoxicity (ADCC) mediated by NK cells in the responder T cell preparation. The likely targets of the ADCC were MoDC that had up‐regulated CD83 during the MLR. Using a 51Cr‐release assay, we confirmed that CD83+ MoDC, but not CD83– MoDC, are lysed by NK cells in the presence of RA83. However, prior fixation of the stimulator MoDC in the allogeneic MLR did not abrogate RA83 inhibition, indicating that cells from the responder T lymphocyte preparation, involved in the MLR proliferative response, also expressed CD83. We found, after 3–4 days of culture with allogeneic MoDC, a subset of CD3+ cells had up‐regulated CD83 and CD25. These were blasting T cells and, when isolated from the MLR, were found to be lysed by autologous NK cells in the presence of RA83. Thus, CD83 is expressed by responding T cells as well as by stimulating cells in the MLR and both are susceptible to anti‐CD83‐mediated ADCC.